Status | In progress |
Decision | Selected |
Process | HST |
ID number | 3764 |
Provisional Schedule
Expected publication | 20 July 2022 |
Project Team
Project lead | Daniel Davies |
Email enquiries
- If you have any queries please email HST@nice.org.uk
External Assessment Group | Peninsula Technology Assessment Group (PenTAG), University of Exeter |
Stakeholders
Companies sponsors | Rhythm Pharmaceuticals (setmelanotide) |
Others | NHS England |
Department of Health and Social Care | |
Welsh Government | |
Patient carer groups | None |
Professional groups | Royal College of Paediatrics & Child Health |
Royal College of Physicians | |
Associated public health groups | None |
Comparator companies | GlaxoSmithKline Consumer Healthcare (orlistat) |
General commentators | All Wales Therapeutics and Toxicology Centre |
British National Formulary | |
Department of Health, Social Services and Public Safety for Northern Ireland | |
Healthcare Improvement Scotland | |
Medicines and Healthcare products Regulatory Agency | |
Scottish Medicines Consortium | |
Welsh Health Specialised Services Committee | |
Relevant research groups | None |
Timeline
Key events during the development of the guidance:
Date | Update |
---|---|
03 June 2022 - 17 June 2022 | Final evaluation determination: 3764 |
13 April 2022 | Committee meeting: 2 |
31 January 2022 - 21 February 2022 | Evaluation consultation |
09 December 2021 | Committee meeting: 1 |
10 May 2021 | Invitation to participate |
07 May 2021 | In progress. In progress |
31 July 2020 (14:00) | Scoping workshop (Manchester) |
08 June 2020 - 06 July 2020 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual